Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Stock data | 2025 | Change |
---|---|---|
Price | $19.70 | N/A |
Market Cap | $715.80M | N/A |
Shares Outstanding | 36.34M | N/A |
Employees | 9.00 | N/A |